PExA to showcase non-invasive lung research platform and present at Respiratory Innovation Summit during ATS 2025
PExA AB, a Swedish life science company and pioneer in non-invasive lung research, will participate in the American Thoracic Society (ATS) 2025 International Conference, taking place May 16–21 in San Francisco, California.
Returning for the third consecutive year, PExA will exhibit at ATS — the world’s leading event for pulmonary, critical care, and sleep medicine. At Booth #256, the company will demonstrate its unique platform for sampling and analyzing aerosol particles from the small airways — the site where many respiratory diseases begin.
This year, PExA will highlight how its technology supports:
- Biomarker discovery in diseases such as COPD, pulmonary embolism and lung cancer
- Pharmacokinetic profiling of inhaled and targeted therapies
- The upcoming Small Airway Atlas™, a first-of-its-kind omics database from the distal lung
In parallel with the exhibition, PExA has been selected as a Featured Poster Company at the Respiratory Innovation Summit (RIS) — a high-profile forum hosted during ATS that convenes global innovators, pharma, investors and clinical leaders.
“We’re proud to be featured at RIS and to return to ATS,” says Tomas Gustafsson, CEO of PExA.
“This year, we’re especially excited to highlight how our technology supports biomarker research that may lead to earlier and more precise detection of serious lung diseases — including lung cancer — by accessing the region where they silently originate.”
The company’s technology is already in use by more than 20 global centers and is backed by over 50 peer-reviewed publications. Ongoing studies cover clinical and preclinical research in COPD, pulmonary embolism, lung cancer, COVID-19 and other major respiratory conditions.
To learn more or to book a meeting at ATS 2025, contact:
Tomas Gustafsson, CEO – tomas.gustafsson@pexa.se
Learn more: conference.thoracic.org
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.